LPTI: AI 评分 57/100 — AI 分析 (4月 2026)

Longport, Inc. specializes in high-resolution ultrasound imaging systems, primarily the EPISCAN I-200, used in various medical and veterinary applications. The company operates in a niche market, focusing on high-frequency ultrasound technology for skin and soft tissue imaging.

Key Facts: AI Score: 57/100 Sector: Healthcare

公司概况

概要：

Longport, Inc. develops and markets high-resolution ultrasound imaging systems, including the EPISCAN I-200, targeting niche applications such as wound assessment, dermatology, and veterinary medicine. With a focus on high-frequency ultrasound technology, the company operates primarily in the United States, facing competition in the broader medical devices market.

LPTI是做什么的？

Founded in 1993 and based in Chadds Ford, Pennsylvania, Longport, Inc. specializes in the development, manufacturing, marketing, and sales of high-resolution ultrasound imaging systems. The company's flagship product is the EPISCAN I-200, a high-frequency ultrasound imaging system operating between 20 and 50MHz. This system is designed to image the skin and underlying soft tissue, offering detailed visualization for various applications. Longport's products are utilized in wound assessment and prevention, clinical dermatology, aesthetics and plastics, burn assessment, superficial musculoskeletal imaging, and veterinary medicine. The company's focus on high-frequency ultrasound technology differentiates it from competitors offering broader ultrasound solutions. Longport's geographic focus is primarily within the United States, while also exporting its products to international markets. The company caters to a specialized segment within the medical devices industry, targeting applications where high-resolution imaging of superficial tissues is critical. Longport's evolution has been centered around refining its EPISCAN technology and expanding its applications across different medical and veterinary fields. With a small team of 8 employees, Longport operates with a lean structure, emphasizing innovation and specialized product development.

LPTI的投资论点是什么？

Longport, Inc. presents a focused investment opportunity within the niche market of high-resolution ultrasound imaging. The company's EPISCAN I-200 system addresses specific needs in dermatology, wound care, and veterinary applications. Key value drivers include expanding the application of EPISCAN technology in new clinical areas and increasing market penetration within the United States. Growth catalysts include potential partnerships with larger medical device companies and securing regulatory approvals for new applications. However, the company's small size and limited financial resources pose risks, particularly in competing with larger players in the medical device industry. The company's negative profit margin of -110.3% and ROE of -120.2% indicate financial challenges that need to be addressed for sustainable growth. The high debt-to-equity ratio of 17.04 also warrants careful consideration.

LPTI在哪个行业运营？

Longport, Inc. operates within the medical devices industry, specifically in the ultrasound imaging segment. The global ultrasound equipment market is projected to reach billions of dollars by 2026, driven by increasing demand for non-invasive diagnostic procedures. The competitive landscape includes major players like General Electric, Siemens, and Philips, as well as smaller specialized companies. Longport differentiates itself through its focus on high-resolution, high-frequency ultrasound technology for niche applications. The company's success depends on its ability to innovate and capture market share in specialized areas such as dermatology and wound care.

Medical - Devices

Healthcare

LPTI有哪些增长机遇？

Expanding into Veterinary Applications: The veterinary market presents a significant growth opportunity for Longport's EPISCAN I-200 system. High-resolution imaging is valuable for diagnosing skin conditions, assessing injuries, and guiding surgical procedures in animals. The veterinary ultrasound market is growing, driven by increasing pet ownership and demand for advanced medical care for animals. Longport can target veterinary clinics and hospitals, offering specialized ultrasound solutions tailored to their needs. This expansion could significantly increase the company's revenue and market presence within the next 2-3 years.
Strategic Partnerships with Dermatology Clinics: Collaborating with dermatology clinics and practices can drive adoption of Longport's EPISCAN I-200 system for skin imaging and diagnostics. By offering training, support, and customized solutions, Longport can establish long-term relationships with key dermatology providers. The dermatology market is growing, driven by increasing demand for cosmetic procedures and skin cancer detection. Strategic partnerships can provide Longport with access to a wider customer base and accelerate sales growth. This initiative can be implemented within the next year.
Developing New Applications for Wound Care: Longport can expand the application of its EPISCAN technology in wound care management. High-resolution ultrasound imaging can be used to assess wound depth, monitor healing progress, and guide treatment decisions. The wound care market is growing, driven by increasing prevalence of chronic wounds and demand for advanced wound care products. Longport can collaborate with wound care centers and hospitals to develop and market specialized ultrasound solutions for wound management. This expansion can be realized within the next 2-3 years through focused research and development.
Securing Regulatory Approvals for New Indications: Obtaining regulatory approvals for new clinical indications can expand the market for Longport's EPISCAN I-200 system. By conducting clinical trials and submitting applications to regulatory agencies, Longport can demonstrate the safety and efficacy of its technology for specific medical conditions. Regulatory approvals can provide a competitive advantage and increase market acceptance of Longport's products. This process typically takes 2-5 years and requires significant investment in research and development.
International Expansion into Europe and Asia: Expanding into international markets, particularly Europe and Asia, can drive long-term growth for Longport. These regions have large and growing healthcare markets with increasing demand for advanced medical technologies. Longport can establish partnerships with distributors and local representatives to market and sell its EPISCAN I-200 system in these regions. International expansion requires careful planning and investment, but it can significantly increase the company's revenue and global presence within the next 3-5 years.

Gross Margin of 52.9% indicates potential for profitability if sales volume increases.
Negative Profit Margin of -110.3% reflects significant operational losses.
Debt-to-Equity Ratio of 17.04 suggests high leverage and potential financial risk.
Market Cap of $0.00B indicates the company's small size and limited market presence.
Beta of -8.30 suggests an inverse correlation with the market, but may be unreliable due to the company's small size and OTC listing.

LPTI提供哪些产品和服务？

Develops high-resolution ultrasound imaging systems.
Manufactures the EPISCAN I-200, a high-frequency ultrasound system.
Markets and sells ultrasound systems primarily in the United States.
Provides imaging solutions for skin and soft tissue assessment.
Offers products for wound assessment, dermatology, and veterinary applications.
Exports its products to international markets.

LPTI如何赚钱？

Direct sales of EPISCAN I-200 ultrasound systems to medical and veterinary professionals.
Service and maintenance contracts for installed ultrasound systems.
Potential revenue from licensing its ultrasound technology.
Sales of consumables and accessories related to the EPISCAN system.

Dermatologists and dermatology clinics.
Wound care centers and hospitals.
Veterinary clinics and animal hospitals.
Plastic surgeons and aesthetic practices.

Specialized high-frequency ultrasound technology for niche applications.
Proprietary EPISCAN I-200 system with unique imaging capabilities.
Established presence in the dermatology and wound care markets.
Potential for strong relationships with specialized medical professionals.

什么因素可能推动LPTI股价上涨？

Upcoming: Potential partnerships with dermatology clinics to expand market reach.
Ongoing: Continued sales and marketing efforts for the EPISCAN I-200 system.
Upcoming: Possible regulatory approvals for new clinical indications.

LPTI的主要风险是什么？

Ongoing: Limited financial resources and negative profitability.
Potential: Competition from larger medical device companies.
Potential: Technological advancements by competitors.
Ongoing: Dependence on a single product (EPISCAN I-200).
Potential: Risks associated with trading on the OTC market.

LPTI的核心优势是什么？

Specialized high-resolution ultrasound technology.
EPISCAN I-200 system caters to niche markets.
Established presence in dermatology and wound care.
Potential for strong relationships with medical professionals.

LPTI的劣势是什么？

Small company with limited financial resources.
Negative profit margin and high debt-to-equity ratio.
Limited market presence compared to larger competitors.
Dependence on a single product (EPISCAN I-200).

LPTI有哪些机遇？

Expanding into veterinary applications.
Strategic partnerships with dermatology clinics.
Developing new applications for wound care.
Securing regulatory approvals for new indications.

LPTI面临哪些威胁？

Competition from larger medical device companies.
Technological advancements by competitors.
Regulatory changes and healthcare reforms.
Economic downturn affecting healthcare spending.

LPTI的竞争对手是谁？

Cutera Inc — Focuses on aesthetic laser and energy-based devices. — (COTQF)
Evasc Medical Systems Corp — Develops endovascular aneurysm repair systems. — (EVARF)
Lucid Diagnostics Inc — Offers esophageal disease diagnostics. — (LCDX)
Life Partners Holdings Inc — Provides life insurance and annuity products. — (LFPI)
Miracor Medical Systems GmbH — Develops cardiac therapies and devices. — (MRRCF)

Key Metrics

MoonshotScore: 57/100

Company Profile

CEO: Michael C. Boyd
Headquarters: Chadds Ford, US
Employees: 8
Founded: 2009

AI Insight

AI analysis pending for LPTI

OTC Tier: OTC Other
Disclosure Status: Unknown

常见问题

What does Longport, Inc. do?

Longport, Inc. develops, manufactures, and markets high-resolution ultrasound imaging systems, primarily the EPISCAN I-200. This system utilizes high-frequency ultrasound to image the skin and underlying soft tissue, catering to niche applications in wound assessment, dermatology, aesthetics, and veterinary medicine. The company focuses on providing specialized imaging solutions for medical and veterinary professionals, differentiating itself through its high-resolution technology and targeted market approach. Longport's business model revolves around direct sales, service contracts, and potential licensing opportunities.

What do analysts say about LPTI stock?

As of 2026-03-17, there is no available analyst coverage for Longport, Inc. due to its small market capitalization and OTC listing. Key valuation metrics such as price-to-earnings ratio and earnings per share are not applicable given the company's negative profitability. Growth considerations depend on Longport's ability to expand its market reach, secure regulatory approvals, and manage its financial challenges. Investors should conduct their own thorough analysis and consider the risks associated with investing in OTC stocks before making any investment decisions.

What are the main risks for LPTI?

The main risks for Longport, Inc. include its limited financial resources, negative profitability, and high debt-to-equity ratio. The company faces competition from larger medical device companies with greater resources and market presence. Technological advancements by competitors could render Longport's products obsolete. Trading on the OTC market poses additional risks, including limited liquidity, potential price manipulation, and lack of regulatory oversight. Dependence on a single product (EPISCAN I-200) also increases the company's vulnerability to market changes and competitive pressures.